Drugs / nL-ASXL3-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07197268 | May 2025 → May 2027 expected | — | n-Lorem Foundation | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-ASXL3-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07197268 ↗ |
| Modality | Antisense oligonucleotide | “individualized antisense oligonucleotide (ASO) treatment” NCT07197268 ↗ |